Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory...

Descripción completa

Detalles Bibliográficos
Autores: Iznardo, Helena|||0000-0002-0710-5521, Puig Sanz, Lluís|||0000-0001-6083-0952
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:255505
Acceso en línea:https://ddd.uab.cat/record/255505
https://dx.doi.org/urn:doi:10.3390/ijms22094344
Access Level:acceso abierto
Palabra clave:Psoriasis
Pustular psoriasis
Psoriatic arthritis
Imsidolimab
Spesolimab
IL-36
IL-36R
Pathogenesis
id ES_cb85637c1aad1d2b7281f60f6bb18e5e
oai_identifier_str oai:ddd.uab.cat:255505
network_acronym_str ES
network_name_str España
repository_id_str
spelling Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic DiseaseIznardo, Helena|||0000-0002-0710-5521Puig Sanz, Lluís|||0000-0001-6083-0952PsoriasisPustular psoriasisPsoriatic arthritisImsidolimabSpesolimabIL-36IL-36RPathogenesisUnmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results. 22021-01-0120212021-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/255505https://dx.doi.org/urn:doi:10.3390/ijms22094344reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2555052026-06-06T12:50:31Z
dc.title.none.fl_str_mv Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
spellingShingle Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
Iznardo, Helena|||0000-0002-0710-5521
Psoriasis
Pustular psoriasis
Psoriatic arthritis
Imsidolimab
Spesolimab
IL-36
IL-36R
Pathogenesis
title_short Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_fullStr Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_full_unstemmed Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
title_sort Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
dc.creator.none.fl_str_mv Iznardo, Helena|||0000-0002-0710-5521
Puig Sanz, Lluís|||0000-0001-6083-0952
author Iznardo, Helena|||0000-0002-0710-5521
author_facet Iznardo, Helena|||0000-0002-0710-5521
Puig Sanz, Lluís|||0000-0001-6083-0952
author_role author
author2 Puig Sanz, Lluís|||0000-0001-6083-0952
author2_role author
dc.subject.none.fl_str_mv Psoriasis
Pustular psoriasis
Psoriatic arthritis
Imsidolimab
Spesolimab
IL-36
IL-36R
Pathogenesis
topic Psoriasis
Pustular psoriasis
Psoriatic arthritis
Imsidolimab
Spesolimab
IL-36
IL-36R
Pathogenesis
description Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/255505
https://dx.doi.org/urn:doi:10.3390/ijms22094344
url https://ddd.uab.cat/record/255505
https://dx.doi.org/urn:doi:10.3390/ijms22094344
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419595378458624
score 15,811543

Similares en LA Referencia